Biofrontera Inc. Files S-1/A Amendment

TL;DR

<b>Biofrontera Inc. has filed an S-1/A amendment, providing updated financial and business information.</b>

AI Summary

Biofrontera Inc. (BFRIW) filed a Amended IPO Registration (S-1/A) with the SEC on January 29, 2024. Biofrontera Inc. filed an S-1/A amendment on January 29, 2024. The company is incorporated in Delaware with its principal business address in Woburn, MA. The filing relates to the Securities Act of 1933. The SIC code for Biofrontera Inc. is 2834 (Pharmaceutical Preparations). The filing includes data for fiscal years ending December 31, 2021, 2022, and periods up to September 30, 2023.

Why It Matters

For investors and stakeholders tracking Biofrontera Inc., this filing contains several important signals. This amendment likely contains crucial updates for investors regarding the company's financial health, strategic direction, or regulatory compliance. Investors and potential investors can use this filing to assess the current status and future prospects of Biofrontera Inc. before making investment decisions.

Risk Assessment

Risk Level: low — Biofrontera Inc. shows low risk based on this filing. The filing is an amendment to a registration statement, indicating ongoing or updated disclosure requirements rather than immediate financial distress.

Analyst Insight

Review the detailed financial statements and risk factors within the S-1/A filing to understand Biofrontera Inc.'s current operational and financial standing.

Key Numbers

• 2024-01-29 — Filing Date (Date of S-1/A filing)
• 2023-09-30 — Most Recent Interim Period End (Financial reporting period)
• 2022-12-31 — Most Recent Fiscal Year End (Financial reporting period)
• 2021-12-31 — Prior Fiscal Year End (Financial reporting period)

Key Players & Entities

• Biofrontera Inc. (company) — Filer name
• 2024-01-29 (date) — Filing date
• S-1/A (document) — Form type
• 1933 Act (regulation) — SEC Act
• 2834 (industry_code) — Standard Industrial Classification
• Woburn, MA (location) — Business address city and state
• 781-245-1325 (phone_number) — Business phone
• DE (location) — State of incorporation

Forward-Looking Statements

• Biofrontera Inc. will proceed with its initial public offering in the near future. (Biofrontera Inc.) — high confidence, target: 2024-06-30

FAQ

Industry Context

Biofrontera Inc. operates in the pharmaceutical preparations industry, focusing on the development and commercialization of medical devices and pharmaceutical products.

Regulatory Implications

The S-1/A filing is made under the Securities Act of 1933, which governs the registration of securities offerings in the United States.

What Investors Should Do

1. Analyze the updated financial statements for revenue, net income, and cash flow.
2. Review any new or revised risk factors disclosed in the amendment.
3. Assess management's discussion and analysis for insights into business strategy and outlook.

Year-Over-Year Comparison

This is an amendment (S-1/A) to a previous filing, indicating updated information is being provided.

Key Financial Figures

• $0.001 — 0 shares of our common stock, par value $0.001 (the "Common Stock") and up to 3,300,00
• $1.51 — t an assumed combined offering price of $1.51 per share and accompanying warrant to p
• $0 — d to the public in this offering, minus $0.0001, and the exercise price of each pr
• $0.0001 — rice of each pre-funded warrant will be $0.0001 per share. The pre-funded warrants will
• $4 billion — market size is estimated to be roughly $4 billion for the three therapy types. Our primar
• $500 million — et, our targeted market is about 11% or $500 million of the total AK market (consisting of t
• $100 million — consisting of the current PDT market at $100 million and the portion of the market attribute
• $400 m — y treatments of more than 14 lesions at $400 million, assuming a tube price of $346).
• $346 — $400 million, assuming a tube price of $346). 6 Our second prescription drug lice

Filing Documents

• forms-1a.htm (S-1/A) — 3533KB
• ex1-1.htm (EX-1.1) — 199KB
• ex4-14.htm (EX-4.14) — 122KB
• ex4-15.htm (EX-4.15) — 115KB
• ex5-1.htm (EX-5.1) — 40KB
• ex10-38.htm (EX-10.38) — 171KB
• ex23-1.htm (EX-23.1) — 3KB
• ex107.htm (EX-FILING FEES) — 27KB
• ex5-1_001.jpg (GRAPHIC) — 17KB
• logo_001.jpg (GRAPHIC) — 12KB
• logo_002.jpg (GRAPHIC) — 9KB
• 0001493152-24-004089.txt (&nbsp;) — 13730KB
• bfri-20230930.xsd (EX-101.SCH) — 88KB
• bfri-20230930_cal.xml (EX-101.CAL) — 104KB
• bfri-20230930_def.xml (EX-101.DEF) — 400KB
• bfri-20230930_lab.xml (EX-101.LAB) — 607KB
• bfri-20230930_pre.xml (EX-101.PRE) — 539KB
• forms-1a_htm.xml (XML) — 1985KB

RISK FACTORS

RISK FACTORS 14 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 50

USE OF PROCEEDS

USE OF PROCEEDS 51 CAPITALIZATION 52 DIVIDEND POLICY 53

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 56

BUSINESS

BUSINESS 71 MANAGEMENT 81

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 86 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 90

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 93

DESCRIPTION OF SECURITIES AND CERTIFICATE OF INCORPORATION

DESCRIPTION OF SECURITIES AND CERTIFICATE OF INCORPORATION 94 SHARES ELIGIBLE FOR FUTURE SALE 101 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS 102 PLAN OF DISTRIBUTION 106 LEGAL MATTERS 112 EXPERTS 112 WHERE YOU CAN FIND MORE INFORMATION 112 INDEX TO FINANCIAL STATEMENTS F-1 i ABOUT THIS PROSPECTUS We have not authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any related free-writing prospectus. We and the Placement Agent take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares and warrants offered by this prospectus, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside the United States: We have not done anything that would permit this offering or the possession or distribution of this prospectus or any free-writing prospectus that we may provide to you in connection with the offering in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares and warrants and the distribution of this prospectus outside the United States. See "Plan of Distribution." BASIS OF PRESENTATION As used in this prospectus, unless the context otherwise requires, references to "we," "us," "our," the "Company," "Biofrontera" and similar references refer to Biofrontera Inc. References in this prospectus to the " Biofrontera Group " refer to Biofrontera AG and its consolidated subsidiaries, Biofrontera Pha

View Full Filing

View this S-1/A filing on SEC EDGAR